We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AbbVie, Halozyme Collaborate
News

AbbVie, Halozyme Collaborate

AbbVie, Halozyme Collaborate
News

AbbVie, Halozyme Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbbVie, Halozyme Collaborate "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under their global collaboration and licensing agreement, AbbVie has agreed to pay Halogen an initial $23 million upfront, followed by payments tied to achieving development, regulatory, and sales-based milestones, totaling about $130 million for each of up to nine collaboration targets.

In addition, AbbVie agreed to pay Halozyme tiered royalties if products under the collaboration are commercialized.

ENHANZE™ is based on a recombinant human hyaluronidase or rHuPH20 that aids in the dispersion and absorption of other injected therapeutic drugs by temporarily degrading hyaluronan.

AbbVie reasons that the platform may enable more rapid delivery of injectable medications through subcutaneous delivery. The platform also holds potential for benefiting users of subcutaneous biologics by reducing the need for multiple injections.

Helen Torley, M.B., Ch.B., Halozyme’s president and CEO, said in a statement that AbbVie joins several biopharma giants in  partnering with Halozyme to develop new formulations of their drugs. These companies include Baxter International, Johnson & Johnson’s Janssen Biotech, Pfizer, and Roche.

Advertisement